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 Abstract 
Objectives: To estimate the co-morbidity associated with Systemic Lupus 
Erythematosus (SLE) in the UK during 1999-2012. 
Methods: A retrospective cohort study using the UK Clinical Practice Research 
Datalink (CPRD) was conducted. Prevalent cases of SLE were matched by age, sex, 
and practice to 4 controls. The incidence of cardiovascular disease (CVD), stroke, 
end-stage renal failure (ESRF), cancer, osteoporosis and infection were calculated 
per 1,000 person-years during the study period and compared to controls using 
Poisson regression to obtain incidence rate ratios (IRR). IRR were adjusted for 
baseline age, gender, body mass index, smoking status, alcohol intake, 
hypertension, hyperlipidaemia, Charlson index and prednisolone use. Age and 
gender-specific incidence rates were calculated. 
Results: Comparing the 7,732 prevalent cases of SLE with 28,079 matched controls 
the unadjusted IRR for CVD was 1.98 (95% CI: 1.69, 2.31), stroke 1.81 (95% CI: 
1.49, 2.19), ESRF 7.81 (95% CI: 4.68, 13.05), cancer 1.28 (95% CI: 1.17, 1.40), 
osteoporosis 2.53 (95% CI: 2.27, 2.82) and infection 1.49 (95% CI: 1.40, 1.58). After 
adjustment, the rates remained significantly higher in cases. Men with SLE had 
higher rates of CVD, stroke and cancer whereas women had higher rates of infection 
and osteoporosis. Those at younger ages were at the greatest relative risk compared 
with controls. Cases had significantly higher Charlson Index scores at baseline.  
Conclusions: People with SLE in the UK have a greater burden of co-morbidity and 
are more likely to develop CVD, stroke, ESRF, cancer, osteoporosis and infection 
than people of the same age and gender.   
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Significance 
 People with SLE in the UK have a greater burden of co-morbidity and are 
more likely to develop CVD, stroke, ESRF, cancer, osteoporosis and infection 
than people of the same age and gender. 
 Those at younger ages are at greatest relative risk compared with people of 
the same age.  
 People with SLE are at increased risk of lung cancer, lymphoma (Hodgkin’s 
and non-Hodgkin) and other haematological malignancies. 
 Clinicians should be aware of these increased risks and target primary 
prevention accordingly by encouraging smoking cessation, minimising steroid 
use, controlling disease activity and regular monitoring of risk factors such as 
blood pressure, lipids and urinalysis. 
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INTRODUCTION 
SLE is a chronic multi-system autoimmune disease characterised by episodes of 
disease flare and remission. Recent studies have found a disease prevalence of 
0.073% in the United States [1 ,2] and 0.097% in the United Kingdom [3] with a 
suggestion that the prevalence of SLE is increasing.[3] SLE is associated with 
significant morbidity which impacts on quality of life [4] and life-expectancy [5 ,6]. 
People with SLE are recognised to be at increased risk of developing certain co-
morbidities such as cardiovascular disease (CVD), [7 ,8] stroke[9], osteoporosis [10-
12] and infection [13-15], with recent guidelines recommending monitoring of risk 
factors for these conditions and institution of preventative treatment.[16] However, 
some studies into CVD and stroke only found an increased risk in young people.[8 ,9 
,17] The majority of osteoporosis studies have focused on women.[10-12] Most 
studies into infection are based in secondary care.[13-15] The risk of malignancy in 
SLE is controversial with conflicting evidence as to whether overall malignancy 
occurs more frequently in people with SLE compared with that of the general 
population or whether people with SLE are at increased risk of certain malignancies 
such as Hodgkin’s lymphoma.[18-22] End-stage renal failure (ESRF) as a 
consequence of lupus nephritis is well documented [23 ,24] but the incidence of 
ESRF in people with SLE is less well studied. The incidence rate of CVD, Stroke, 
ESRF, cancer and infection have not previously been studied from a community 
perspective in a large SLE population in the UK. We therefore aimed to estimate the 
current incidence of CVD, stroke, ESRF, cancer, osteoporosis and infection in 
people with SLE in the UK for the period 1999-2012 by age and gender from a 
community perspective. 
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METHOD 
Study design and source population 
A retrospective cohort study was conducted using the Clinical Practice Research 
Datalink (CPRD). The CPRD is a longitudinal database of general practice records 
deemed to be representative of the UK population which has been described in 
detail previously.[3 ,25] Data are entered at the practice level using Read codes, and 
anonymised records are accessed by researchers from a central database or annual 
release of flat files. As of January 2013 there were primary care records from 660 
practices for approximately 12 million people in all four countries of the UK.  
For this study participants were males and females contributing data during the study 
period 1st January 1999 to 31st December 2012. Participants were eligible from the 
date their practice was deemed to be contributing “up-to-standard” (UTS) data as 
verified by the CPRD. 
Study sample 
The study sample included a cohort of cases and controls. Cases were prevalent 
cases of SLE who had one of 14 Read codes for SLE (list available on request) and 
were on the CPRD meeting the eligibility criteria on the 1st July of each calendar 
year of the study period. Controls were age (within 5 years), sex and practice-
matched individuals contributing data during the study period to the CPRD without 
SLE matched in a 1:4 ratio. Controls were given an index date the same as the 
diagnosis date of the matched case.  
For this study the entry date was the latest of 1st January 1999, SLE diagnosis or 
matched index date, registration plus 365 days and UTS date. The exit date was the 
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earliest date of transfer-out of the participating practice, death, date of development 
of the co-morbidity or 31st December 2012.  
Outcome measures  
The six specific co-morbidities chosen for estimation were CVD, stroke, ESRF, 
cancer, osteoporosis and infection. In addition, the incidence rates for selected 
cancer sites were estimated. Read code lists for each co-morbidity are available on 
request. Co-morbidities were scored as 1 for present and 0 for absent. 
A Charlson Index score was calculated at baseline (study entry date) for cases and 
controls using all diagnoses in the records following practice registration and UTS 
date and prior to baseline start date. The Charlson Index [26] is a validated weighted 
co-morbidity score which contains 17 diagnostic categories: myocardial infarction, 
congestive heart failure, peripheral vascular disease, cerebrovascular disease, 
dementia, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, 
mild liver disease, moderate or severe liver disease, diabetes mellitus (DM), DM with 
chronic complications, renal diseases, any malignancy (including leukaemia and 
lymphoma), metastatic solid tumour and human immunodeficiency virus (HIV) 
infection. Each category is assigned a score of 1 to 6, depending on mortality risk, 
and a cumulative score is calculated for each individual. With increasing score there 
is a stepwise increased risk of death. Charlson comorbidity index was categorised as 
0, 1-2, 3-5 and >5. SLE was excluded from the score to ensure comparability 
between cases and controls.  
The following confounding variables were searched for in the records of eligible 
participants: Body Mass Index (BMI) (categorised as underweight (BMI<19) , normal 
(BMI 19-25), overweight (BMI 26-29), obese (BMI30-39), severely obese (BMI≥40), 
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or missing), smoking status (non-smoker, smoker, ex-smoker or missing), alcohol 
intake (none, alcohol in moderation, alcohol excess, ex-drinker, missing), 
hypertension (yes or no, yes defined as either a record of hypertension in the clinical 
notes or 2 or more blood pressure (BP) readings with systolic BP>140mmHg and/or 
diastolic BP>90mmHg prior to study entry), hyperlipidaemia (yes or no, yes defined 
as either a record of hyperlipidaemia in the clinical notes or a laboratory reading of 
total cholesterol>5mmol/l, HDL cholesterol<1mmol/l, non-HDL cholesterol>4mmol/l, 
triglycerides>1.7mmol/l, LDL cholesterol>3mmol/l, cholesterol:HDL ratio>4 or 
HDL:LDL ratio>4.5 prior to study entry) and prednisolone prescription within the year 
prior to study entry (yes or no). Where there was more than one record for BMI, 
smoking status or alcohol intake the closest record to the study entry date was 
chosen.  
Statistical analysis 
Differences in baseline Charlson Index and confounding variables between cases 
and controls were compared using Chi-squared test. 
The incidence rate in cases for each co-morbidity or cancer site was calculated by 
dividing the number of SLE cases who developed the co-morbidity by the number of 
person-years for people with SLE during follow-up. Cases with the selected co-
morbidity at baseline were excluded. Due to the frequency and acute nature of 
infections the analysis was repeated for infection without excluding individuals with 
an infection prior to diagnosis date as a comparison. Crude incidence rates of co-
morbidities were calculated with 95% confidence intervals (CI) using the stptime 
command in Stata which assumes a Poisson distribution. Sex- and age-specific SLE 
co-morbidity incidence rates were calculated for the study period and expressed as 
per 1,000 person-years. Age was grouped into <40 years, 40-69 years and 
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70+years. The incidence rates in cases were compared with the incidence rate in 
controls using Poisson regression to obtain an incidence rate ratio (IRR). Overall IRR 
were adjusted for age at baseline, gender, baseline Charlson Index and the 
confounding variables listed above.[27] Significance of IRR was tested using 
likelihood ratios. 
Data management and analysis was performed using StataMP4 software, version 13 
(Statacorp, Texas, USA). Independent Scientific Advisory Committee (ISAC) for 
MHRA Database Research approval was gained for this study on 4th June 2013 
(Protocol 13_092). 
RESULTS 
There were 7,732 prevalent cases of SLE and 28,079 matched controls. Baseline 
demographics are shown in table 1. There was a significant trend for BMI, alcohol, 
smoking and Charlson Index suggesting that controls had a higher BMI and drank 
more alcohol whereas cases were more likely to smoke and have a higher baseline 
Charlson Index. Cases were significantly more likely to have hypertension or 
hyperlipidaemia and have used prednisolone in the year before study entry. The 
median follow-up time for cases (8.4 years, (IQR 3.7, 12.8 years)) was shorter than 
that for controls (10.8 years (IQR: 5.8, 13.9 years)) (p<0.001). 
Table 2 shows the incidence rates in cases and controls and IRRs for each of the six 
co-morbidities during the study period. The incidence rates of all six co-morbidities 
were significantly higher in people with SLE compared with controls (all p values 
<0.001) and remained significant after adjustment for age, gender and other 
confounding variables. The rate of infection remained significantly higher in people 
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with SLE regardless of whether cases or controls with an infection prior to baseline 
were excluded (p<0.001). 
Gender differences: The incidence rates of the co-morbidities by gender are shown 
in Table 3. For both men and women SLE cases had higher rates of all co-
morbidities compared to controls (p<0.001). Men with SLE had higher incidence 
rates of CVD, stroke and cancer compared to women with SLE, whereas women had 
higher rates of infection and osteoporosis. This was also true of matched controls. 
Despite having a lower absolute risk, men with SLE had a higher relative risk for 
osteoporosis than women.  
Age differences: Table 4 shows the difference in age-specific incidence for each co-
morbidity. Within every age group cases had a higher incidence of every co-
morbidity than controls, although this was not significant for those aged over 70 
years for ESRF and cancer. In cases, the incidence of CVD, stroke, cancer and 
osteoporosis increased with age, the incidence of infection remained stable and the 
incidence of ESRF reduced with age. Compared with controls, the greatest risk for 
all co-morbidities except infection was at younger ages. Age group overall had a 
significant effect on all co-morbidities apart from infection and cancer. 
Cancer sites: Table 5 shows the incidence rates of cancer sites in cases compared 
with controls and table 6 shows the incidence rates of those cancers that were only 
or predominantly found in women. After adjustment for confounders people with SLE 
were at significantly increased risk of lung cancer, lymphoma (Hodgkin’s and non-
Hodgkin) and other haematological malignancies.  
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DISCUSSION 
This study found an increased incidence rate of co-morbidity in people with SLE. 
People with SLE were more likely to develop CVD, stroke, ESRF, cancer, 
osteoporosis and infection than people without SLE. Men with SLE had higher 
incidence rates of CVD, stroke and cancer compared to women with SLE, whereas 
women had higher incidence rates of infection and osteoporosis. Those at younger 
ages were at the greatest relative risk of co-morbidity compared with people of the 
same age.  
Previous studies have found an association between SLE and the development of 
certain comorbidities. The increased incidence rate of CVD and stroke found in our 
study is consistent with findings from previous studies.[5 ,7-9 ,17] However, in 
contrast to Ward [8], Mok et al. [9] and Bengtsson et al [17] we found an increased 
incidence rate of CVD and stroke across all age groups not just younger ages. 
Although we found those at the youngest age groups had the greatest relative risk 
(for CVD: IRR 40.31 95% CI: 5.11-318.14 for age <40 years vs 1.41 95% CI: 1.09-
1.82 aged >70 years) those at older ages had the greatest absolute risk. This may 
be because our study was from a community rather than a secondary care 
perspective. Men with SLE had higher incidence rates of CVD and stroke than 
women with SLE, but this is likely to reflect the background population risk as this 
was also true of male compared with female controls. Reasons for the increased 
vascular risk in SLE appear to be due to a combination of increased conventional 
risk factors for atherosclerosis such as hypertension, diabetes mellitus and 
hypercholesterolemia, in conjunction with added risks caused by chronic 
inflammation, secondary anti-phospholipid syndrome, renal failure, early menopause 
and long-term steroid-therapy.[28 ,29]  In our study the rate in cases remained 
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significantly higher than controls even after adjusting for age, gender, smoking, 
hypertension, hyperlipidaemia, BMI, prednisolone use and baseline Charlson Index 
which included diabetes and renal disease. Clearly primary prevention applies to all 
age groups but physicians need to remember to target both young and older people. 
Increased awareness of these risks in conjunction with good disease control and 
recommended monitoring and primary prevention strategies [16] should reduce the 
rates of CVD and stroke in future.  
ESRF had the biggest difference in incidence rates between cases and controls, 
even after adjustment. Although the confidence intervals were wide, the incidence of 
ESRF decreased with age in cases but increased with age in controls. This may be 
because people with SLE who develop lupus nephritis and subsequently ESRF 
develop it early in the disease process. This would fit with previous research which 
found that although people with SLE could develop ESRF at any time the greatest 
risk was in the first 5-10 years following diagnosis.[30]  
The incidence of infection was increased in SLE cases compared to controls 
regardless of whether people with previous infections were excluded. Consistent with 
previous studies the increase in infection rate in SLE is considered to be partly due 
to the disease process itself, but also due to the immunosuppressant drugs used to 
treat SLE. [13-15] Adjusting for steroid use reduced the rate ratio, but it remained 
significant, suggesting this increase was in part due to the SLE itself or residual 
confounding, for example due to use of other immunosuppressants. 
Our study found an increase in the incidence rate of cancer overall. This supports 
the findings from a recent large international study [21] which found people with SLE 
had a small increased risk of cancer overall (standardised incidence rate 1.14, 95% 
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CI: 1.05-1.23). Our study also confirmed the increased risk of lung cancer, 
lymphoma (Hodgkin’s and non-Hodgkin) and other haematological malignancies 
which have been found previously.[21 ,22] However, we did not find a significantly 
increased risk of vulval, thyroid or pancreatic cancer or significantly reduced risks of 
breast and endometrial cancers which have been previously reported. [20 ,21]. 
Disordered immune surveillance, immunosuppressive drugs, and an increase in 
“usual” risk factors for malignancy such as smoking have been suggested as 
hypotheses for the increased malignancy risk in SLE.[19] Patients should therefore 
be encouraged to modify behavioural risks such as smoking which was increased at 
baseline in people with SLE in this study and report new symptoms of persistent 
cough, haemoptysis, enlarged lymph glands or the occurrence of night sweats, 
fevers and unexplained weight loss (B symptoms). 
The rate of osteoporosis was increased for both males and females with SLE. Most 
previous research has focused on women with SLE [10 ,11 ,31] and although women 
had higher incidence rates of osteoporosis, men with SLE were at a much greater 
relative risk compared to their controls. The increased risk of osteoporosis is 
considered to be due to steroid usage, disease process and, in women, premature 
menopause.[18] Clinicians need to continue to be vigilant of this risk, minimising 
steroid usage and screening when appropriate, including men. 
Despite excluding SLE from the score, the Charlson Index in people with SLE was 
raised at baseline, suggesting that people with SLE have an increased global burden 
of comorbidity compared with controls. This score was developed to predict future 
mortality [26] suggesting further work should be carried out to reduce this risk to 
reduce premature mortality in SLE. 
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The main advantage of this study was the large sample size available through the 
CPRD and hence the generalizability of results to the UK population. This study is 
the first to examine the incidence of CVD, stroke, cancer, ESRF and infection in a 
large cohort of SLE patients from a community perspective compared with age and 
sex- matched controls in the UK. The main limitation of this study is that we were 
reliant on the accuracy of data entry at the GP practices and therefore there may 
have been miscoded data, which may have introduced misclassification bias, and 
missing data, for example as found for our confounding variables particularly BMI 
where approximately 37% of participants had no BMI recorded. There is potential 
ascertainment bias for comorbidities in cases if they were receiving more regular 
follow-up. It was not possible to classify all participants with a code for cancer due to 
the use of non-specific Read codes such as “Neoplasm”. Not all cancer sites were 
explored. There may be residual confounding due to variables not considered for 
adjustment, such as immunosuppressant use. Finally, we used prevalent cases to 
increase our cohort size, but in doing so we may have missed severely ill incident 
cases who were diagnosed and died before the start of the study period. This may 
have biased the sample towards the less severe prevalent cases who survived. 
In summary, we found in a large UK community-based cohort people with SLE had 
greater co-morbidity than people without SLE. This was found in a global baseline 
co-morbidity score and specifically in the incidence of CVD, stroke, ESRF, cancer, 
osteoporosis and infection. Men with SLE had higher incidence rates of CVD, stroke 
and cancer whereas women had higher incidence rates of infection and 
osteoporosis. Young people with SLE were at the greatest relative risk of CVD, 
stroke, ESRF and osteoporosis compared with people of the same age, although 
people of older age were at greater absolute risk of CVD, stroke and osteoporosis. 
14 
 
Clinicians should be aware of these increased risks and target primary prevention 
accordingly by encouraging smoking cessation, controlling disease activity, 
minimising steroid use and regular monitoring of risk factors such as blood pressure, 
lipids and urinalysis. Ongoing research is required to explain why people with SLE 
are at increased risk beyond the “usual” risk factors to enable refinement of primary 
prevention strategies to reduce the excess morbidity associated with SLE. 
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Table 1: Demographics and confounding variables at baseline 
 Cases (%) 
N=7,732 
Controls (%) 
N=28,079 
P value 
Gender    
Male 1,098 (14.2) 3,980 (14.2)  
Female 6,634 (85.8) 24,099 (85.8) 0.953
a 
    
Age    
Mean age at baseline, years 
(SD) 
48.1 (17.1) 48.1 (17.2) 0.903
 c
 
    
Disease duration at baseline    
Median time from index date to 
baseline, years (IQR) 
2.4 (0-9.3) 2.9 (0-9.1) 0.003
d 
    
BMI    
Underweight 145 (1.9) 376 (1.3)  
Normal 2,227 (28.8) 7,744 (27.6)  
Overweight 1,255 (16.2) 4,950 (17.6)  
Obese 1,028 (13.3) 3,899 (13.9)  
Severely obese 177 (2.3) 624 (2.2)  
Missing 2,900 (37.5) 13,486 (37.3) <0.001
 b
 
Smoking    
Non-smoker 4,056 (52.5) 16,673 (59.4)  
Smoker 2,154 (27.9) 6,328 (22.5)  
Ex-smoker 1,330 (17.2) 4,412 (15.7)  
Missing 192 (2.5) 666 (2.4) <0.001
 b
 
Alcohol    
Non-drinker 1,861 (23.9) 5,800 (20.7)  
Drinks alcohol  4,775 (61.8) 18,366 (65.4)  
Drinks alcohol over limits 78 (1.0) 348 (1.2)  
Ex-drinker 181 (2.3) 446 (1.6)  
Missing 847 (11.0) 3,119 (11.1) <0.001
 b
 
Charlson Index    
0 4,382 (56.7) 21,094 (75.1)  
1-2 2,668 (34.5) 6,060 (21.6)  
3-5 615 (8.0) 850 (3.0)  
>5 67 (0.9) 75 (0.3)  <0.001
 b
 
    
Hypertension    
No 7,006 (90.6) 25,651 (91.4)  
Yes 726 (9.4) 2,428 (8.7)  0.041
 a
 
    
Hyperlipidaemia    
No 6,096 (79) 22,945 (82)  
Yes 1,636 (21) 5,134 (18) <0.001
 a
 
    
Prednisolone use in year 
before baseline 
   
No 6,024 (78) 27,419 (98)  
Yes 1,708 (22) 660 (2) <0.001
 a
 
    
a= Chi-squared, b= Chi-squared p for trend, c= t-test, d=Wilcoxon rank-sum 
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Table 2 Incidence rates of co-morbidity 
Co-morbidity Case-
control 
status 
Number 
of 
eligible 
people  
Person- 
years  
Number 
of people 
who 
developed 
co-
morbidity 
IR of co-morbidity, per 
1,000 person-years 
(95% CI) 
IRR (95% CI)
 e
 Adjusted IRR (95% 
CI)
b e
 
Adjusted IRR (95% 
CI)
c e
 
CVD controls 26,683 203,135 533 2.62 (2.41 2.86)          
 cases 7,033 44,177 229 5.18 (4.55 5.90) 1.98 (1.69 2.31) 2.14 (1.83 2.50) 1.65 (1.40 1.95) 
                 
Stroke controls 27,295 210,019 369 1.76 (1.59 1.95)          
 cases 7,291 46,265 147 3.18 (2.70 3.73) 1.81 (1.49 2.19) 1.95 (1.61 2.36) 1.47 (1.20 1.80) 
                 
ESRF controls 27,560 213,055 23 0.11 (0.07 0.16)          
 cases 7,440 47,432 40 0.84 (0.62 1.15) 7.81 (4.68 13.05) 7.83 (4.69 13.08) 3.41 (1.93 6.05) 
                 
Cancer controls 25,111 184,470 2,142 11.61 (11.13 12.11)          
 cases 6,636 40,366 599 14.84 (13.70 16.08) 1.28 (1.17 1.40) 1.31 (1.20 1.44) 1.15 (1.05 1.27) 
                
Osteoporosis controls 27,030 205,413 925 4.50 (4.22 4.80)          
 cases 7,048 42,838 488 11.39 (10.42 12.45) 2.53 (2.27 2.82) 2.71 (2.43 3.03) 1.92 (1.70 2.16) 
                 
Infection controls 10,067 46,219 5,665 122.57 (119.42 125.80)          
 cases 1,984 6,497 1,183 182.09 (172.01 192.77) 1.49 (1.40 1.58) 1.48 (1.39 1.57) 1.10 (1.03 1.18) 
                 
Infection
a 
controls 27,527 98,388 18,119 184.16 (181.50 186.86)          
 cases 7,420 17,586 5,240 297.97 (290.01 306.15) 1.62 (1.57 1.67) 1.62 (1.57 1.67) 1.35 (1.26 1.44) 
a
=not excluding co-morbidity at baseline. b = adjusted for age and gender. c = b plus alcohol, smoking, hypertension, hyperlipidaemia, BMI, prednisolone use, 
and baseline Charlson index. 
e
all p<0.001 CVD=cardiovascular disease. ESRF=end-stage renal failure.
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Table 3 Gender-specific incidence rates of co-morbidity  
Co-morbidity Gender IR of co-morbidity, per 
1,000 person-years (95% 
CI) in controls 
IR of co-morbidity, per 
1,000 person-years (95% 
CI) in cases 
IRR (cases compared 
with controls) 
e
 (95% CI) 
CVD Males 5.46 (4.67 6.39) 8.34 (6.30 11.03) 1.53 (1.11 2.10) 
 Females 2.16 (1.96 2.39) 4.70 (4.06 5.44) 2.17 (1.82 2.59) 
           
Stroke Males 2.60 (2.08 3.24) 5.06 (3.60 7.12) 1.95 (1.30 2.93) 
 Females 1.61 (1.44 1.81) 2.87 (2.39 3.45) 1.78 (1.43 2.21) 
           
ESRF  Males 0.06 (0.02 0.26) 1.19 (0.59 2.38) 18.55 (3.94 87.36) 
 Females 0.12 (0.08 0.18) 0.79 (0.56 1.11) 6.81 (3.93 11.80) 
           
Cancer Males 13.47 (12.16 14.92) 19.15 (15.88 23.08) 1.42 (1.15 1.76) 
 Females 11.29 (10.78 11.83) 14.12 (12.93 15.43) 1.25 (1.13 1.38) 
           
Osteoporosis Males 1.16 (0.84 1.61) 6.22 (4.56 8.47) 5.35 (3.41 8.40) 
 Females 5.10 (4.77 5.44) 12.31 (11.22 13.50) 2.41 (2.16 2.70) 
           
Infection Males 94.11 (87.85 100.82) 150.67 (129.98 174.66) 1.60 (1.36 1.88) 
 Females 129.09 (125.51 132.77) 188.98 (177.66 201.02) 1.46 (1.37 1.57) 
e
all p<0.01, CVD=cardiovascular disease. ESRF=end-stage renal failure, IR=incidence rate, IRR=incidence rate ratio 
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Table 4 Age-specific incidence rates of co-morbidity 
Co-morbidity Age group 
(years) 
IR of co-morbidity, per 1,000 
person-years (95% CI) in controls 
IR of co-morbidity, per 1,000 
person-years (95% CI) in cases 
IRR (cases compared 
with controls) (95% CI) 
P value 
CVD <40 0.03 (0.00 0.18) 1.03 (0.54 1.98) 40.31 (5.11 318.14)  
 40-69 1.96 (1.73 2.22) 5.17 (4.40 6.08) 2.64 (2.15 3.24)  
 70+ 7.27 (6.48 8.16) 10.24 (8.15 12.86) 1.41 (1.09 1.82) <0.001 
Stroke <40 0.08 (0.02 0.24) 1.15 (0.62 2.14) 15.00 (4.13 54.49)  
 40-69 0.86 (0.71 1.04) 2.19 (1.71 2.79) 2.54 (1.87 3.47)  
 70+ 5.83 (5.16 6.59) 8.79 (6.99 11.06) 1.51 (1.16 1.95) <0.001 
ESRF  <40 0.03 (0.00 0.18) 1.61 (0.95 2.72) 63.06 (8.29 479.56)  
 40-69 0.08 (0.04 0.15) 0.77 (0.51 1.16) 9.83 (4.68 20.66)  
 70+ 0.26 (0.15 0.46) 0.34 (0.11 1.05) 1.30 (0.37 4.61) <0.001 
Cancer <40 4.63 (3.99 5.37) 5.58 (4.18 7.45) 1.21 (0.87 1.67)  
 40-69 10.15 (9.57 10.75) 14.53 (13.12 16.08) 1.43 (1.27 1.61)  
 70+ 23.68 (22.12 25.34) 27.62 (23.88 31.94) 1.17 (0.99 1.37) 0.1066 
Osteoporosis <40 0.31 (0.17 0.54) 3.62 (2.55 5.15) 11.80 (6.06 22.97)  
 40-69 3.19 (2.90 3.52) 10.75 (9.59 12.06) 3.37 (2.90 3.92)  
 70+ 12.42 (11.39 13.54) 23.32 (20.01 27.18) 1.88 (1.58 2.24) <0.001 
Infection <40 156.88 (148.52 165.71) 210.76 (187.84 236.46) 1.34 (1.18 1.53)  
 40-69 114.59 (110.70 118.62) 171.49 (159.05 184.89) 1.50 (1.38 1.63)  
 70+ 107.20 (101.21 113.54) 184.22 (161.17 210.56) 1.58 (1.36 1.82) 0.2248 
CVD=cardiovascular disease. ESRF=end-stage renal failure, IR=incidence rate, IRR=incidence rate ratio 
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Table 5: Incidence rates of cancer by site 
Cancer site Case 
status 
Person-
time 
Number of people 
with cancer site 
Incidence rate, per 1,000 
person-years (95% CI)  
IRR (95%  CI) Adjusted IRR
a 
(95% 
CI) 
Breast  Control 184,771 361 1.95 (1.76 2.17)       
 Case 40,445 65 1.61 (1.26 2.05) 0.82 (0.63 1.07) 0.85 (0.65 1.13) 
Lung  Control 184,480 44 0.24 (0.18 0.32)       
 Case 40,365 37 0.92 (0.66 1.27) 3.84 (2.48 5.95)* 3.27 (2.06 5.18)* 
Colorectal Control 184,508 96 0.52 (0.43 0.64)       
 Case 40,374 19 0.47 (0.30 0.74) 0.90 (0.55 1.48) 0.91 (0.54 1.53) 
Hodgkin's lymphoma Control 184,487 6 0.03 (0.01 0.07)       
 Case 40,371 5 0.12 (0.05 0.30) 3.81 (1.16 2.48)* 3.55 (1.01 12.51)* 
Non-Hodgkin’s  Control 184,507 49 0.27 (0.20 0.35)       
Lymphoma Case 40,377 31 0.77 (0.54 1.09) 2.89 (1.84 4.53)* 2.44 (1.48 4.02)* 
Other  Control 184,509 65 0.35 (0.28 0.45)       
haematological Case 40,387 35 0.87 (0.62 1.21) 2.46 (1.63 3.71)* 2.43 (1.56 3.78)* 
Pancreas Control 184,469 14 0.08 (0.04 0.13)       
 Case 40,378 10 0.25 (0.13 0.46) 3.26 (1.45 7.35)* 1.92 (0.74 5.00) 
Liver or biliary tree Control 184,470 8 0.04 (0.02 0.09)       
 Case 40,366 3 0.07 (0.02 0.23) 1.71 (0.45 6.46) 1.56 (0.38 6.45) 
Melanoma Control 184,515 65 0.35 (0.28 0.45)       
 Case 40,375 11 0.27 (0.15 0.49) 0.77 (0.41 1.47) 0.82 (0.42 1.60) 
Non-melanoma  Control 185,016 610 3.30 (3.05 3.57)       
skin cancer Case 40,512 148 3.65 (3.11 4.29) 1.11 (0.93 1.33) 1.08 (0.89 1.31) 
Bladder Control 184,501 51 0.28 (0.21 0.36)       
 Case 40,383 9 0.22 (0.12 0.43) 0.81 (0.40 1.64) 0.69 (0.33 1.46) 
Renal Control 184,471 19 0.10 (0.07 0.16)       
 Case 40,372 3 0.07 (0.02 0.23) 0.72 (0.21 2.44) 0.64 (0.17 2.38) 
*P<0.05, aadjusted for age and gender, alcohol, smoking, hypertension, BMI, baseline Charlson index, hyperlipidaemia, and 
prednisolone use in the past year, IRR=incidence rate ratio 
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Table 6: Incidence rates by cancer site for women only 
Cancer site Case 
status 
Person-
time 
Number of people 
with cancer site 
Incidence rate, per 1,000 
person-years (95% CI) 
IRR (95%  CI) Adjusted IRR
a 
(95% 
CI) 
Breast  Control 157,603 360 2.28 (2.06 2.53)       
 Case 34,700 64 1.84 (1.44 2.36) 0.81 (0.62 1.05) 0.85 (0.64 1.13) 
Thyroid Control 157,302 8 0.05 (0.03 0.10)       
 Case 34,630 4 0.12 (0.04 0.31) 2.27 (0.68 7.54) 1.37 (0.33 5.74) 
Cervix Control 157,339 25 0.16 (0.11 0.24)       
 Case 34,646 9 0.26 (0.14 0.50) 1.63 (0.76 3.50) 1.86 (0.82 4.22) 
Ovary Control 157,325 29 0.18 (0.13 0.27)       
 Case 34,634 11 0.32 (0.18 0.57) 1.72 (0.86 3.45) 1.28 (0.58 2.80) 
Vulval Control 157,303 10 0.06 (0.03 0.12)       
 Case 34,620 5 0.14 (0.06 0.35) 2.27 (0.78 6.65) 1.04 (0.30 3.64) 
Uterus Control 157,359 39 0.25 (0.18 0.34)       
 Case 34,624 7 0.20 (0.10 0.42) 0.82 (0.36 1.82) 1.04 (0.45 2.38) 
aadjusted for age and gender, alcohol, smoking, hypertension, BMI, baseline Charlson index, hyperlipidaemia, and prednisolone 
use in the past year, IRR=incidence rate ratio 
 
 
 
